Latest News

Santen and Glaukos Enter into Collaboration and Distribution Agreement for Exclusive Distribution of the MicroShunt (DE-128) in the United States

OSAKA, Japan & SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Santen Pharmaceutical Co., Ltd. (“Santen” TSE: 4536) and Glaukos Corporation (“Glaukos” NYSE: GKOS), announced today that Santen’s U.S. subsidiary, Santen Inc., has entered into a multi-year agreement whereby Glaukos will become the exclusive distributor of the MicroShunt (development code: DE-128) solely in the U.S. market. The MicroShunt is a novel, minimally-invasive, ab-externo surgical device being developed for primary open-angle glauc

Source link

Related posts

Skilled health workforce in India does not meet WHO recommended threshold


Feeling Very Sleepy During Daytime Linked To Alzheimer's Risk


Diet comprising of soups and shakes may combat obesity


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy